Critical characteristics for corticosteroid solution metered dose inhaler bioequivalence.

Determining bioequivalence for solution pressurized metered dose inhalers (pMDI) is difficult because the critical characteristics of such products are poorly defined. The aim of this study was to elucidate the non-aerodynamic properties of the emitted aerosol particles from two solution pMDI products that determine their biopharmaceutical differences after deposition. Novel particle capture and analysis techniques were employed to characterize the physicochemical and biopharmaceutical properties of two beclomethasone dipropionate (BDP) products: QVAR and Sanasthmax. The BDP particles emitted from the Sanasthmax inhaler were discernibly different those emitted from QVAR in terms of size (50% larger, less porous), solid state (less crystalline) and dissolution (20-fold slower). When deposited onto the surface of respiratory epithelial cell layers, QVAR delivered ∼50% more BDP across the cell layer in 60 min than Sanasthmax. Biopharmaceutical performance was not attributable to individual particle properties as these were manifold with summative and/or competing effects. The cell culture dissolution-absorption model revealed the net effect of the particle formed on drug disposition and was predictive of human systemic absorption of BDP delivered by the test inhalers. This illustrates the potential of the technique to detect the effect of formulation on the performance of aerosolized particles and contribute to assessment of bioequivalence.

[1]  Zengri J. Wang,et al.  Bioequivalence of Press- and- Breathe and Breath-Actuated Inhalers of Beclomethasone Dipropionate Extrafine Aerosol , 2002 .

[2]  Peter Meredith,et al.  Bioequivalence and other unresolved issues in generic drug substitution. , 2003, Clinical therapeutics.

[3]  S. Newman,et al.  Improved targeting of beclomethasone diproprionate (250 μg metered dose inhaler) to the lungs of asthmatics with the Spacehaler , 1999 .

[4]  L. Harrison,et al.  Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics. , 1998, Respiratory medicine.

[5]  R. Tiner,et al.  Aerosol drug delivery: developments in device design and clinical use , 2011, The Lancet.

[6]  A. Kirschbaum,et al.  Monitoring the initial pulmonary absorption of two different beclomethasone dipropionate aerosols employing a human lung reperfusion model , 2005, Respiratory research.

[7]  R. B. Walker,et al.  Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  Hugh D C Smyth,et al.  The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. , 2003, Advanced drug delivery reviews.

[9]  G. Colice,et al.  Particle size of inhaled corticosteroids: does it matter? , 2009, The Journal of allergy and clinical immunology.

[10]  Robert Combes,et al.  In vitro models of inhalation toxicity and disease. The report of a FRAME workshop. , 2009, Alternatives to laboratory animals : ATLA.

[11]  Extra-fine corticosteroid aerosols from hydrofluoroalkane-134a metered-dose inhalers: potential advantages and disadvantages. , 1999, Chest.

[12]  B. Rothen‐Rutishauser,et al.  A novel cell compatible impingement system to study in vitro drug absorption from dry powder aerosol formulations. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[13]  B. Müller,et al.  Metered-dose inhaler formulations with beclomethasone-17,21-dipropionate using the ozone friendly propellant R 134a. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[14]  Ben Forbes,et al.  Culture of Calu-3 Cells at the Air Interface Provides a Representative Model of the Airway Epithelial Barrier , 2006, Pharmaceutical Research.

[15]  A. Hickey,et al.  Development of a Size-dependent Aerosol Deposition Model Utilising Human Airway Epithelial Cells for Evaluating Aerosol Drug Delivery , 2004, Alternatives to laboratory animals : ATLA.

[16]  E. Ormsby,et al.  Metered-dose inhalers, I: Drug content and particle size distribution of beclomethasone dipropionate. , 1996, Journal of pharmaceutical and biomedical analysis.

[17]  R. Pauwels,et al.  Pharmacokinetic and Pharmacodynamic Properties of Inhaled Beclometasone Dipropionate Delivered Via Hydrofluoroalkane-Containing Devices , 2005, Clinical pharmacokinetics.

[18]  B. Forbes,et al.  In vivo and in vitro characterization of novel microparticulates based on hyaluronan and chitosan hydroglutamate , 2001, AAPS PharmSciTech.

[19]  Svetlana Lyapustina,et al.  Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report. , 2010, Journal of aerosol medicine and pulmonary drug delivery.

[20]  G. P. Martin,et al.  The permeability of large molecular weight solutes following particle delivery to air-interfaced cells that model the respiratory mucosa. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[21]  N Lotan,et al.  Large porous particles for pulmonary drug delivery. , 1997, Science.

[22]  O. Usmani,et al.  Regional Lung Deposition and Bronchodilator Response as a Function of β2-Agonist Particle Size , 2005 .

[23]  G. P. Martin,et al.  Integrated in vitro experimental modelling of inhaled drug delivery: deposition, dissolution and absorption , 2011 .

[24]  A. Woodcock,et al.  Modulite technology: pharmacodynamic and pharmacokinetic implications. , 2002, Respiratory medicine.

[25]  C. Leach Improved delivery of inhaled steroids to the large and small airways. , 1998, Respiratory medicine.

[26]  C. Leach,et al.  Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone : a cross-over study in healthy volunteers. , 2002, Chest.

[27]  H. Ortega,et al.  Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing , 2009, Clinical therapeutics.